PolyPid Ltd.

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Medical Devices
    • Biomaterials
  • Biotechnology
See more in Biomedtracker

Latest on PolyPid Ltd.

Scrip

Scrip Asks… What Does 2025 Hold For Biopharma? Part 2: Funding, M&A And Partnering

 
• By Eleanor Malone

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Scrip

Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

Scrip

Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone

 
• By Mandy Jackson

Many public biopharmaceutical companies have turned to alternatives other than follow-on public offerings (FOPOs) this year to fund their research and development programs while stock prices have been

Scrip

PolyPid’s D-PLEX100 May Have Way Forward Despite Phase III Miss

 
• By Alaric DeArment

PolyPid Ltd. ’s Phase III SHIELD I trial of D-PLEX100 for preventing surgical site infections (SSIs) among patients receiving abdominal surgery failed to be the successful trial that analysts had thou